228 related articles for article (PubMed ID: 10615328)
1. [Amoxicillin/clavulanic acid (875/125 mg). New pharmacodynamic aspects].
Lode H
Dtsch Med Wochenschr; 1999 Dec; 124(48):1459-61. PubMed ID: 10615328
[No Abstract] [Full Text] [Related]
2. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
[TBL] [Abstract][Full Text] [Related]
3. A pharmacodynamic model to support a 12-hour dosing interval for amoxicillin/sulbactam, a novel oral combination, in the treatment of community-acquired lower respiratory tract infections.
Bantar C; Nicola F; Fernandez Canigia L; Arenoso HJ; Soutric J; Montoto M; Blanco M; Smayevsky J; Jasovich A
J Chemother; 2000 Jun; 12(3):223-7. PubMed ID: 10877517
[TBL] [Abstract][Full Text] [Related]
4. [Antimicrobial susceptibility of Streptococcus pyogenes, Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis from community acquired respiratory infections in 2000].
Melo-Cristino J; Fernandes ML; Serrano N;
Acta Med Port; 2001; 14(5-6):459-68. PubMed ID: 11878155
[TBL] [Abstract][Full Text] [Related]
5. Exacerbation of COPD: amoxicillin + clavulanic acid in vitro activity vs S. pneumoniae, H. influenzae and M. catarrhalis.
Beghi G; Legnani D; De Bartolo A; Pagani N; Lusco G
J Chemother; 1995 Nov; 7 Suppl 4():61-2. PubMed ID: 8904109
[No Abstract] [Full Text] [Related]
6. Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute purulent bacterial bronchitis.
Dere WH; Farlow D; Therasse DG; Jacobson KD; Guerra FJ
Clin Ther; 1992; 14(2):166-77. PubMed ID: 1611641
[TBL] [Abstract][Full Text] [Related]
7. Eradication of pathogens from the nasopharynx after therapy of acute maxillary sinusitis with low- or high-dose amoxicillin/clavulanic acid.
Brook I; Foote PA; Hausfeld JN
Int J Antimicrob Agents; 2005 Nov; 26(5):416-9. PubMed ID: 16226017
[TBL] [Abstract][Full Text] [Related]
8. Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute bacterial exacerbations of chronic bronchitis.
Zeckel ML; Jacobson KD; Guerra FJ; Therasse DG; Farlow D
Clin Ther; 1992; 14(2):214-29. PubMed ID: 1611645
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activity of the new macrolide flurithromycin against Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Branhamella catarrhalis and Staphylococcus aureus.
Nord CE; Lindmark A; Persson I
J Chemother; 1989 Jul; 1(4 Suppl):203-4. PubMed ID: 16312369
[No Abstract] [Full Text] [Related]
10. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
11. Empirical treatment of influenza-associated pneumonia in primary care: a descriptive study of the antimicrobial susceptibility of lower respiratory tract bacteria (England, Wales and Northern Ireland, January 2007-March 2010).
Blackburn RM; Henderson KL; Lillie M; Sheridan E; George RC; Deas AH; Johnson AP
Thorax; 2011 May; 66(5):389-95. PubMed ID: 21357586
[TBL] [Abstract][Full Text] [Related]
12. [In vitro comparative activity of moxifloxacin and other antimicrobials against respiratory pathogens].
Prado V; Giangrieco M; Durán C; Ojeda A; van Flaskamp R
Rev Med Chil; 2000 Dec; 128(12):1319-26. PubMed ID: 11227240
[TBL] [Abstract][Full Text] [Related]
13. Amoxicillin/clavulanate therapy of respiratory tract infections: a microbiologic perspective.
Cunha BA
Clin Ther; 1992; 14(3):418-25. PubMed ID: 1638583
[TBL] [Abstract][Full Text] [Related]
14. Respiratory tract infection: epidemiology and surveillance.
Jacobs MR
J Chemother; 1997 May; 9 Suppl 3():10-7. PubMed ID: 9248976
[TBL] [Abstract][Full Text] [Related]
15. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics.
Harrison CJ; Woods C; Stout G; Martin B; Selvarangan R
J Antimicrob Chemother; 2009 Mar; 63(3):511-9. PubMed ID: 19174454
[TBL] [Abstract][Full Text] [Related]
16. Activity of amoxycillin/clavulanic acid (augmentin) against beta-lactamase-positive S. aureus, H. influenzae and B. catarrhalis in an in vitro kinetic model.
Cooper CE; Slocombe B; White AR
J Chemother; 1989 Jul; 1(4 Suppl):350-1. PubMed ID: 16312434
[No Abstract] [Full Text] [Related]
17. [Choice of antibiotics in lower respiratory infections: what does pharmacodynamics bring? Clinical application of pharmacodynamic data].
Goldstein F
Presse Med; 1998 Sep; 27 Suppl 4():22-3. PubMed ID: 9798483
[No Abstract] [Full Text] [Related]
18. [Pharmacodynamic basis for the use of amoxicillin-clavulanic acid in respiratory infections due to Streptococcus pneumoniae: In vitro studies in an experimental model].
Gómez-Lus ML; García Y; Valero E; Amores R; Fuentes F
Rev Esp Quimioter; 2000 Sep; 13(3):306-13. PubMed ID: 11086282
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic resistance. Epidemiology of resistance--respiratory tract infections.
Thomson CJ
J Med Microbiol; 1997 Jun; 46(6):442-5. PubMed ID: 9379469
[No Abstract] [Full Text] [Related]
20. Cefpodoxime proxetil in the treatment of lower respiratory tract infections.
Geddes AM
Drugs; 1991; 42 Suppl 3():34-40. PubMed ID: 1726206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
